Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

FGF23 induces left ventricular hypertrophy
Christian Faul, … , Martin G. Keane, Myles Wolf
Christian Faul, … , Martin G. Keane, Myles Wolf
Published October 10, 2011
Citation Information: J Clin Invest. 2011;121(11):4393-4408. https://doi.org/10.1172/JCI46122.
View: Text | PDF
Research Article Nephrology Article has an altmetric score of 31

FGF23 induces left ventricular hypertrophy

  • Text
  • PDF
Abstract

Chronic kidney disease (CKD) is a public health epidemic that increases risk of death due to cardiovascular disease. Left ventricular hypertrophy (LVH) is an important mechanism of cardiovascular disease in individuals with CKD. Elevated levels of FGF23 have been linked to greater risks of LVH and mortality in patients with CKD, but whether these risks represent causal effects of FGF23 is unknown. Here, we report that elevated FGF23 levels are independently associated with LVH in a large, racially diverse CKD cohort. FGF23 caused pathological hypertrophy of isolated rat cardiomyocytes via FGF receptor–dependent activation of the calcineurin-NFAT signaling pathway, but this effect was independent of klotho, the coreceptor for FGF23 in the kidney and parathyroid glands. Intramyocardial or intravenous injection of FGF23 in wild-type mice resulted in LVH, and klotho-deficient mice demonstrated elevated FGF23 levels and LVH. In an established animal model of CKD, treatment with an FGF–receptor blocker attenuated LVH, although no change in blood pressure was observed. These results unveil a klotho-independent, causal role for FGF23 in the pathogenesis of LVH and suggest that chronically elevated FGF23 levels contribute directly to high rates of LVH and mortality in individuals with CKD.

Authors

Christian Faul, Ansel P. Amaral, Behzad Oskouei, Ming-Chang Hu, Alexis Sloan, Tamara Isakova, Orlando M. Gutiérrez, Robier Aguillon-Prada, Joy Lincoln, Joshua M. Hare, Peter Mundel, Azorides Morales, Julia Scialla, Michael Fischer, Elsayed Z. Soliman, Jing Chen, Alan S. Go, Sylvia E. Rosas, Lisa Nessel, Raymond R. Townsend, Harold I. Feldman, Martin St. John Sutton, Akinlolu Ojo, Crystal Gadegbeku, Giovana Seno Di Marco, Stefan Reuter, Dominik Kentrup, Klaus Tiemann, Marcus Brand, Joseph A. Hill, Orson W. Moe, Makoto Kuro-o, John W. Kusek, Martin G. Keane, Myles Wolf

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2009 Total
Citations: 19 58 74 87 93 69 85 83 76 66 72 91 84 43 1 1 1002
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2012 (43)

Title and authors Publication Year
FGF23 neutralization improves secondary hyperparathyroidism and osteodystrophy parameters yet exacerbates vascular calcification in chronic kidney disease rats
Victoria Shalhoub, Edward M Shatzen, Sabrina Ward, James Davis, Jennitte Stevens, Vivian Bi, Lisa Renshaw, Nessa Hawkins, Wei Wang, Ching Chen, Mei-Mei Tsai, Russell C Cattley, Thomas J Wronski, Xuechun Xia, Xiaodong Li, Charles Henley, Michael Eschenberg, William G Richards
Journal of Clinical Investigation 2012
Fibroblast Growth Factor 23: Friend or Foe in Uremia?
Orson Moe
Journal of Clinical Investigation 2012
Metabolic acidosis increases fibroblast growth factor 23 in neonatal mouse bone
NS Krieger, CD Culbertson, K Kyker-Snowman, DA Bushinsky
American journal of physiology. Renal physiology 2012
Calcitriol, calcidiol, parathyroid hormone, and fibroblast growth factor-23 interactions in chronic kidney disease
JF de Galvao, LA Nagode, PA Schenck, DJ Chew
Journal of Veterinary Emergency and Critical Care 2012
A Comparative Transcriptome Analysis Identifying FGF23 Regulated Genes in the Kidney of a Mouse CKD Model
B Dai, V David, A Martin, J Huang, H Li, Y Jiao, W Gu, LD Quarles
PloS one 2012
The osteocyte in CKD: New concepts regarding the role of FGF23 in mineral metabolism and systemic complications
K Wesseling-Perry, H Jüppner
Bone 2012
Fibroblast growth factor 23: state of the field and future directions
N Bhattacharyya, WH Chong, RI Gafni, MT Collins
Trends in Endocrinology & Metabolism 2012
Update on fibroblast growth factor 23 in chronic kidney disease
M Wolf
Kidney International 2012
Fibroblast Growth Factor-23 Helps Explain the Biphasic Cardiovascular Effects of Vitamin D in Chronic Kidney Disease
P Hu, Q Xuan, B Hu, L Lu, J Wang, YH Qin
International journal of biological sciences 2012
FGF23 production by osteocytes
LF Bonewald, MJ Wacker
Pediatric Nephrology 2012
Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease:
T Isakova
Current Opinion in Nephrology and Hypertension 2012
Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes
J Bacchetta, JL Sea, RF Chun, TS Lisse, K Wesseling-Perry, B Gales, JS Adams, IB Salusky, M Hewison
Journal of Bone and Mineral Research 2012
FGF23 suppresses chondrocyte proliferation in the presence of soluble α-Klotho both in vitro and in vivo
M Kawai, S Kinoshita, A Kimoto, Y Hasegawa, K Miyagawa, M Yamazaki, Y Ohata, K Ozono, T Michigami
The Journal of biological chemistry 2012
Regression of Vascular Calcification in Chronic Kidney Disease - Feasible or Fantasy - a review of the clinical evidence: Regression of Vascular Calcification in Chronic Kidney Disease
O Leonard, J Spaak, D Goldsmith
British Journal of Clinical Pharmacology 2012
Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart
J Xie, SK Cha, SW An, M Kuro-O, L Birnbaumer, CL Huang
Nature Communications 2012
FGF23 and PTH--double agents at the heart of CKD
J Silver, M Rodriguez, E Slatopolsky
Nephrology Dialysis Transplantation 2012
Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity?
J Bacchetta, IB Salusky, M Hewison
Pediatric Nephrology 2012
The role of FGF23 in CKD—with or without Klotho
H Komaba, M Fukagawa
Nature Reviews Nephrology 2012
Hypophosphatemia and growth
F Santos, R Fuente, N Mejia, L Mantecon, H Gil-Peña, FA Ordoñez
Pediatric Nephrology 2012
FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1/2–SGK1 signaling pathway
O Andrukhova, U Zeitz, R Goetz, M Mohammadi, B Lanske, RG Erben
Bone 2012
Non-Systemic Drugs: A Critical Review
D Charmot
Current pharmaceutical design 2012
Bone Biomarkers Help Grading Severity of Coronary Calcifications in Non Dialysis Chronic Kidney Disease Patients
M Morena, I Jaussent, A Halkovich, AM Dupuy, AS Bargnoux, L Chenine, H Leray-Moragues, K Klouche, H Vernhet, B Canaud, JP Cristol
PloS one 2012
An update on uremic toxins
N Neirynck, R Vanholder, E Schepers, S Eloot, A Pletinck, G Glorieux
International Urology and Nephrology 2012
Phosphate is a vascular toxin
R Shroff
Pediatric Nephrology 2012
Cardiorenal syndrome: pathophysiology and potential targets for clinical management
P Hatamizadeh, GC Fonarow, MJ Budoff, S Darabian, CP Kovesdy, K Kalantar-Zadeh
Nature Reviews Nephrology 2012
Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled
U Elewa, MD Sanchez-Niño, C Martin-Cleary, B Fernandez-Fernandez, J Egido, A Ortiz
International Urology and Nephrology 2012
Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet
WL Lau, EM Leaf, MC Hu, MM Takeno, M Kuro-o, OW Moe, CM Giachelli
Kidney International 2012
What's new in FGF23 research?
S Fukumoto
BoneKEy Reports 2012
Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol
T Isakova, H Xie, A Barchi-Chung, K Smith, N Sowden, M Epstein, G Collerone, L Keating, H Jüppner, M Wolf
Clinical journal of the American Society of Nephrology : CJASN 2012
Mineral metabolites and CKD progression in African Americans
JJ Scialla, BC Astor, T Isakova, H Xie, LJ Appel, M Wolf
Journal of the American Society of Nephrology : JASN 2012
Effects of phosphate binders in moderate CKD
GA Block, DC Wheeler, MS Persky, B Kestenbaum, M Ketteler, DM Spiegel, MA Allison, J Asplin, G Smits, AN Hoofnagle, L Kooienga, R Thadhani, M Mannstadt, M Wolf, GM Chertow
Journal of the American Society of Nephrology : JASN 2012
FGF-23 and the progression of coronary arterial calcification in patients new to dialysis
AM Khan, JA Chirinos, H Litt, W Yang, SE Rosas
Clinical journal of the American Society of Nephrology : CJASN 2012
Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD
K Smith, C deFilippi, T Isakova, OM Gutiérrez, K Laliberte, S Seliger, W Kelley, SH Duh, M Hise, R Christenson, M Wolf, J Januzzi
American journal of kidney diseases : the official journal of the National Kidney Foundation 2012
The emerging role of Klotho in clinical nephrology
MC Hu, M Kuro-o, OW Moe
Nephrology Dialysis Transplantation 2012
Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study)
JH Ix, R Katz, BR Kestenbaum, IH de Boer, M Chonchol, KJ Mukamal, D Rifkin, DS Siscovick, MJ Sarnak, MG Shlipak
Journal of the American College of Cardiology 2012
FGF-23 levels in patients with AKI and risk of adverse outcomes
DE Leaf, M Wolf, SS Waikar, H Chase, M Christov, S Cremers, L Stern
Clinical journal of the American Society of Nephrology : CJASN 2012
FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy
S Lundberg, AR Qureshi, S Olivecrona, I Gunnarsson, SH Jacobson, TE Larsson
Clinical journal of the American Society of Nephrology : CJASN 2012
Npt2b Deletion Attenuates Hyperphosphatemia Associated with CKD
SC Schiavi, W Tang, C Bracken, SP OBrien, W Song, J Boulanger, S Ryan, L Phillips, S Liu, C Arbeeny, S Ledbetter, Y Sabbagh
Journal of the American Society of Nephrology : JASN 2012
Associations between Kidney Function and Subclinical Cardiac Abnormalities in CKD
M Park, C Hsu, Y Li, RK Mishra, M Keane, SE Rosas, D Dries, D Xie, J Chen, J He, A Anderson, AS Go, MG Shlipak
Journal of the American Society of Nephrology : JASN 2012
The Association of Parathyroid Hormone with ESRD and Pre-ESRD Mortality in the Kidney Early Evaluation Program
G Saab, AS Bomback, SI McFarlane, S Li, SC Chen, PA McCullough, A Whaley-Connell
The Journal of clinical endocrinology and metabolism 2012
Fibroblast Growth Factor 23 and Inflammation in CKD
JM Mendoza, T Isakova, AC Ricardo, H Xie, SD Navaneethan, AH Anderson, LA Bazzano, D Xie, M Kretzler, L Nessel, LL Hamm, L Negrea, MB Leonard, D Raj, M Wolf
Clinical journal of the American Society of Nephrology : CJASN 2012
Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: An analysis of the MASTERPLAN cohort
Vervloet MG, van Zuilen AD, Heijboer AC, ter Wee PM, Bots ML, Blankestijn PJ, Wetzels JF
BMC Nephrology 2012
Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis.
Seeherunvong W, Abitbol CL, Chandar J, Rusconi P, Zilleruelo GE, Freundlich M
Pediatric nephrology (Berlin, Germany) 2012

← Previous 1 2 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Blogged by 1
Posted by 8 X users
Referenced in 17 patents
Referenced in 6 Wikipedia pages
Highlighted by 1 platforms
Referenced in 1 clinical guideline sources
656 readers on Mendeley
1 readers on CiteULike
See more details